default author photo

Bryan Fellman

University of Texas at Houston - MD Anderson Cancer Center

Unit 1905

Houston, TX

United States

SCHOLARLY PAPERS

4

DOWNLOADS

139

TOTAL CITATIONS

0

Scholarly Papers (4)

1.

Phase II Trial of Pembrolizumab in Combination with Chemotherapy for Frontline Treatment of Advanced Epithelial Ovarian Cancer

Number of pages: 44 Posted: 28 Mar 2024
University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Texas Oncology, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Texas Oncology, University of Texas at Houston - Department of Genomic Medicine and University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine
Downloads 49 (1,074,648)

Abstract:

Loading...

pembrolizumab, combination chemotherapy, ovarian cancer, immunotherapy, tumor immune microenvironment, translational, clinical trial, feasibility

2.

Hormonal Therapy in Low-Grade Endometrial Stromal Sarcoma; What is the Current Standard of Care?

Number of pages: 25 Posted: 30 May 2024
affiliation not provided to SSRN, University of Texas at Houston - MD Anderson Cancer Center, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, affiliation not provided to SSRN, University of Texas at Houston - MD Anderson Cancer Center and affiliation not provided to SSRN
Downloads 44 (1,133,231)

Abstract:

Loading...

Endometrial Stromal Sarcoma, low-grade ESS, uterine sarcoma, hormonal therapy, Megace, Letrozole

3.

Bevacizumab Beyond Progression: Impact of Subsequent Bevacizumab Re-Treatment in Patients with Ovarian, Fallopian Tube, and Peritoneal Cancer after Progression

Number of pages: 25 Posted: 08 Oct 2024
affiliation not provided to SSRN, affiliation not provided to SSRN, University of Colorado Anschutz Medical Campus, University of Texas at Houston - MD Anderson Cancer Center, Duke University - Medical Center, Columbia University College of Physicians and Surgeons, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, affiliation not provided to SSRN, Duke University and University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine
Downloads 27 (1,359,097)

Abstract:

Loading...

ovarian cancer, fallopian tube cancer, bevacizumab, angiogenesis inhibitors

4.

Phase 1b Study of Batiraxcept (AVB-S6-500) in Combination with Durvalumab (MEDI4736) in Patients with Platinum-Resistant Ovarian Cancer

Number of pages: 27 Posted: 01 Feb 2024
University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Aravive Biologics, Inc., Aravive Biologics, Inc., University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine and University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine
Downloads 19 (1,459,862)

Abstract:

Loading...

immune checkpoint inhibitor, AXL inhibitor, Batiraxcept, platinum-resistant ovarian cancer